Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

Niagen Bioscience highlighted newly published independent preclinical research in Nature Communications identifying the CD38 enzyme as a primary driver of age-related NAD+ decline in placental tissue. The study found older mothers had lower placental NAD+ levels, and restoring NAD+ with nicotinamide riboside (NR) improved placental, fetal, and offspring outcomes in aged mice. Notably, Niagen did not conduct, fund, or design the study, and the NR used was not the company's Niagen ingredient — the release is mechanism-supportive evidence rather than direct product data.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.